Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study

Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has been shown to increase bone mineral density (BMD) and reduce the risk of fracture in postmenopausal women with osteoporosis. Cessation of denosumab is associated with rises in bone remodelling, reductions in BMD and an in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Khan, Aliya, Alrob, Hajar Abu, Said, Hosay, Iqbal, Salman, Hweija, Ismail, Hussain, Sharjil
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Bone and Mineral Metabolism
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090192/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.489
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars